

**CALDERA DESARA
510(K) SUMMARY**

Date of Summary: July 29, 2013

I. Applicant: Caldera Medical, Inc.
5171 Clareton Drive
Agoura Hills, CA 91301
Tel: (805) 879-6555 Fax: (818) 879-6556

Contact: Christine Emanuel
Caldera Medical, Inc.
28632 Roadside Drive, Suite 260
Agoura Hills, CA 91301
Tel: (866) 422-5337 Fax: (818) 879-6556
cemanuel@west.net

2. Device Name: Surgical Mesh (878.3300)
Trade Name: Desara
Common Name: Surgical Mesh
Device Class: Class II, Product Code OTN, 21 CFR 878.3300,
Gynecologic, For Stress Urinary Incontinence,
Female, Obstetrics/Gynecology Panel

3. Predicate Device Caldera T-Sling, K050516, Feb 3, 2006

4. Description of Device

The Caldera Desara Mesh is sterile, single-use pubourethral sling used to provide support in the pelvic region to treat stress urinary incontinence, mixed incontinence, and vaginal vault prolapse. The device is manufactured out of a monofilament polypropylene yarn, which is knitted into a mesh. The device has integral sleeve and sutures to assist the surgeon in placement of the device. The sleeve and sutures are removed after placement of the device.

The Desara Mesh device is a modification to the Caldera T-Sling, used for the same Indications for Use and manufactured out of the same mesh material, a monofilament polypropylene mesh

5. Intended Use of Device

The Desara Mesh is intended to be used in females to position a mesh for the treatment of Genuine Stress Urinary Incontinence (SUI), mixed incontinence resulting from urethral hypermobility or intrinsic sphincter deficiency.

6. Summary of Technological Characteristics

The Caldera Desara device has the same materials and design as the Caldera T-Sling and has the same technological characteristics. The changes to the Desara Mesh are minor and are primarily related to changes in suppliers as well as minor changes to mesh configuration.



Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center – WO66-G609
Silver Spring, MD 20993-0002

September 13, 2013

Caldera Medical, Inc.
% Mara Korsunsky
Quality Assurance and Regulatory Affairs Manager
28632 Roadside Drive, Suite 260
Agoura Hills, CA 91301

Re: K072456
Trade/Device Name: Desara™ Implant
Regulation Number: 21 CFR§ 878.3300
Regulation Name: Surgical mesh
Regulatory Class: II
Product Code: OTN
Dated (Date on orig SE ltr): April 7, 2008
Received (Date on orig SE ltr): April 8, 2008

Dear Mara Korsunsky,

This letter corrects our substantially equivalent letter of May 8, 2008.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act

or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

Herbert P. Lerner -S

for

Benjamin R. Fisher, Ph.D.
Director
Division of Reproductive, Gastro-Renal,
and Urological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): K072456

Device Name: Desara® Mesh

Indications for Use:

The Desara® Mesh is intended to be used in females to position a mesh for the treatment of Genuine Stress Urinary Incontinence (SUI), mixed incontinence resulting from urethral hypermobility or intrinsic sphincter deficiency.

Prescription Use ☒
(21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use ☐
(21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF
NEEDED

Concurrence of CDRH, Office of Device Evaluation (ODE)

Page 1 of 1

Herbert P. Lerner -S